These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20701066)

  • 1. Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
    Bono AV; Pannellini T; Liberatore M; Montironi R; Cunico SC; Cheng L; Sasso F; Musiani P; Iezzi M
    Anal Quant Cytol Histol; 2010 Jun; 32(3):136-45. PubMed ID: 20701066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma.
    Ozawa MG; Yao VJ; Chanthery YH; Troncoso P; Uemura A; Varner AS; Kasman IM; Pasqualini R; Arap W; McDonald DM
    Cancer; 2005 Nov; 104(10):2104-15. PubMed ID: 16208706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
    Raina K; Rajamanickam S; Singh RP; Deep G; Chittezhath M; Agarwal R
    Cancer Res; 2008 Aug; 68(16):6822-30. PubMed ID: 18701508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006).
    Murphy DA; Makonnen S; Lassoued W; Feldman MD; Carter C; Lee WM
    Am J Pathol; 2006 Nov; 169(5):1875-85. PubMed ID: 17071608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade.
    Li H; Gerald WL; Benezra R
    Cancer Res; 2004 Sep; 64(17):6137-43. PubMed ID: 15342397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis and prostate cancer: identification of a molecular progression switch.
    Huss WJ; Hanrahan CF; Barrios RJ; Simons JW; Greenberg NM
    Cancer Res; 2001 Mar; 61(6):2736-43. PubMed ID: 11289156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Montico F; Kido LA; Hetzl AC; Cagnon VH
    Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
    Mateus PAM; Kido LA; Silva RS; Cagnon VHA; Montico F
    Prostate; 2019 Apr; 79(5):515-535. PubMed ID: 30585351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of castration on the development of prostate adenocarcinoma from its precursor HGPIN and on the occurrence of androgen-independent, poorly differentiated carcinoma in TRAMP mice.
    Bono AV; Montironi R; Pannellini T; Sasso F; Mirone V; Musiani P; Iezzi M
    Prostate Cancer Prostatic Dis; 2008; 11(4):377-83. PubMed ID: 18379588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP).
    da Silva RF; Nogueira-Pangrazi E; Kido LA; Montico F; Arana S; Kumar D; Raina K; Agarwal R; Cagnon VHA
    J Biomed Sci; 2017 May; 24(1):31. PubMed ID: 28499383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of angiogenesis inhibitors in prostate cancer.
    Aragon-Ching JB; Dahut WL
    Cancer J; 2008; 14(1):20-5. PubMed ID: 18303479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor endothelial cells join the resistance.
    Dudley AC; Klagsbrun M
    Clin Cancer Res; 2009 Aug; 15(15):4787-9. PubMed ID: 19638456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
    Narayanan BA; Narayanan NK; Pittman B; Reddy BS
    Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemopreventive Effects of Korean Angelica versus Its Major Pyranocoumarins on Two Lineages of Transgenic Adenocarcinoma of Mouse Prostate Carcinogenesis.
    Tang SN; Zhang J; Wu W; Jiang P; Puppala M; Zhang Y; Xing C; Kim SH; Jiang C; Lü J
    Cancer Prev Res (Phila); 2015 Sep; 8(9):835-44. PubMed ID: 26116406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels.
    Wang Z; Hu J; Qiu SJ; Huang XW; Dai Z; Tan CJ; Zhou J; Fan J
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1039-45. PubMed ID: 21671804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model.
    Isayeva T; Chanda D; Kallman L; Eltoum IE; Ponnazhagan S
    Cancer Res; 2007 Jun; 67(12):5789-97. PubMed ID: 17575146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of initiation of angiogenesis in early stages of prostate adenocarcinoma development and progression in a transgenic murine model.
    Gabril M; Xuan J; Moussa M; Dinney CP; Chin JL; Izawa JI
    Urology; 2004 Dec; 64(6):1233-7. PubMed ID: 15596214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease.
    Kang BH; Tavecchio M; Goel HL; Hsieh CC; Garlick DS; Raskett CM; Lian JB; Stein GS; Languino LR; Altieri DC
    Br J Cancer; 2011 Feb; 104(4):629-34. PubMed ID: 21285984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-inflammatory therapies in TRAMP mice: delay in PCa progression.
    Kido LA; Montico F; Sauce R; Macedo AB; Minatel E; Costa DB; Carvalho JE; Pilli RA; Cagnon VH
    Endocr Relat Cancer; 2016 Apr; 23(4):235-50. PubMed ID: 26772819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
    Mancuso MR; Davis R; Norberg SM; O'Brien S; Sennino B; Nakahara T; Yao VJ; Inai T; Brooks P; Freimark B; Shalinsky DR; Hu-Lowe DD; McDonald DM
    J Clin Invest; 2006 Oct; 116(10):2610-21. PubMed ID: 17016557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.